EFFECT OF CAPTOPRIL ON PROGRESSION TO CLINICAL PROTEINURIA IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS AND MICROALBUMINURIA
Citation
G. Viberti et al., EFFECT OF CAPTOPRIL ON PROGRESSION TO CLINICAL PROTEINURIA IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS AND MICROALBUMINURIA, JAMA, the journal of the American Medical Association, 271(4), 1994, pp. 275-279
Categorie Soggetti
Medicine, General & Internal
SICI code
0098-7484(1994)271:4<275:EOCOPT>2.0.ZU;2-J
Abstract
Objectives.-To study the effect of angiotensin converting enzyme inhib
ition on the rate of progression to clinical proteinuria and the rate
of change of albumin excretion rates in patients with insulin-dependen
t diabetes mellitus and persistent microalbuminuria. Design and Settin
g.-Randomized, double-blind, placebo-controlled clinical trial of 2 ye
ars' duration at 12 hospital-based diabetes centers. Patients.-Ninety-
two patients with insulin-dependent diabetes mellitus and persistent m
icroalbuminuria but no hypertension. Intervention.-The patients were r
andomly allocated in blocks of two to receive either captopril, 50 mg,
or placebo twice per day. Measurements.-Albumin excretion rate, blood
pressure, glycosylated hemoglobin level, and fructosamine level every
3 months; urinary urea nitrogen excretion every 6 months; and glomeru
lar filtration rate every 12 months. Results.-Twelve patients receivin
g placebo and four receiving captopril progressed to clinical proteinu
ria, defined as an albumin excretion rate persistently greater than 20
0 mug/min and at least a 30% increase from baseline (P=.05). The proba
bility of progression to clinical proteinuria was significantly reduce
d by captopril therapy (P=.03 by log-rank test Albumin excretion rate
rose from a geometric mean (95% confidence interval) of 52 (39 to 68)
to 76 (47 to 199) mug/min in the placebo group but fell from 52 (41 to
65) to 41 (28 to 60) mug/min in the captopril group, a significant di
fference (P<.01). Mean blood pressure was similar at baseline in the t
wo groups and remained unchanged in the placebo group but fell signifi
cantly, by 3 to 7 mm Hg, in the captopril group. Glycosylated hemoglob
in levels and glomerular filtration rate remained stable in the two gr
oups. Conclusions.-Captopril therapy significantly impeded progression
to clinical proteinuria and prevented the increase in albumin excreti
on rate in nonhypertensive patients with insulin-dependent diabetes me
llitus and persistent microalbuminuria.